HomeMarketsDiscoverWatchlistPortfoliosScreener
Summary of all time highs, changes and price drops for Heartland Group Holdings
Historical stock prices Current Share Price NZ$1.76 52 Week High NZ$2.59 52 Week Low NZ$1.72 Beta 1.14 1 Month Change -6.38% 3 Month Change -7.85% 1 Year Change -23.14% 3 Year Change 9.32% 5 Year Change -3.30% Change since IPO 104.65%
Heartland Group Holdings Limited announced that they will report fiscal year 2022 final results at 10:00 AM, NZST - New Zealand Standard on Sep 28, 2022
Heartland Group Holdings Limited announced that they will report fiscal year 2022 final results at 10:00 AM, NZST - New Zealand Standard on Sep 28, 2022
After last week's 16% share price decline to NZ$1.79, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 11x in the Banks industry in Oceania. Total returns to shareholders of 35% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at NZ$2.60 per share.
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Over the last 90 days, the stock is down 11%. The fair value is estimated to be NZ$2.60, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has grown by 7.2%. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings is also forecast to grow by 9.9% per annum over the same time period.
Heartland Group Holdings Limited has completed a Follow-on Equity Offering in the amount of NZD 130 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 72,222,222 Price\Range: NZD 1.8 Discount Per Security: NZD 0.018 Transaction Features: Subsequent Direct Listing
7D | -2.8% | -1.0% | -1.4% |
1Y | -23.1% | -8.0% | -17.0% |
Return vs Industry: HGH underperformed the NZ Banks industry which returned -8% over the past year.
Return vs Market: HGH underperformed the NZ Market which returned -17% over the past year.
HGH Average Weekly Movement | 4.5% |
Banks Industry Average Movement | 3.7% |
Market Average Movement | 3.8% |
10% most volatile stocks in NZ Market | 8.0% |
10% least volatile stocks in NZ Market | 2.7% |
Stable Share Price: HGH is not significantly more volatile than the rest of NZ stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HGH's weekly volatility (4%) has been stable over the past year.
Heartland Group Holdings Limited provides various financial services in New Zealand and Australia. The company offers savings accounts, term deposits, and direct and business call accounts. It also provides home loans, business loans, term loans, revolving credit, car loans, and reverse mortgage lending and other financial services.
Market Cap | NZ$1.24b |
Earnings (TTM) | NZ$95.13m |
Revenue (TTM) | NZ$253.79m |
Is HGH overvalued?
See Fair Value and valuation analysisRevenue | NZ$253.79m |
Cost of Revenue | NZ$0 |
Gross Profit | NZ$253.79m |
Other Expenses | NZ$158.67m |
Earnings | NZ$95.13m |
Last Reported Earnings Jun 30, 2022 Next Earnings Date Sep 27, 2022 How did HGH perform over the long term?Earnings per share (EPS) 0.13 Gross Margin 100.00% Net Profit Margin 37.48% Debt/Equity Ratio 319.6%
We’ve recently updated our valuation analysis.
Is HGH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Which metric is best to use when looking at relative valuation for HGH?
Other financial metrics that can be useful for relative valuation.
n/a Ratio | 0x |
n/a | n/a |
Market Cap | NZ$1.24b |
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | 1.5x |
How does HGH's PE Ratio compare to its peers?
Peer Average | 9.9x | ||
13.5x | n/a | NT$23.5b | |
BJTM Bank Pembangunan Daerah Jawa Timur | 7x | 19.3% | Rp10.8t |
5.1x | 9.8% | zł3.3b | |
RCB Rizal Commercial Banking | 4.8x | n/a | ₱42.7b |
HGH Heartland Group Holdings | 13.1x | 8.5% | NZ$1.2b |
Price-To-Earnings vs Peers: HGH is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (9.9x).
How does HGH's PE Ratio compare vs other companies in the Global Banks Industry?
Price-To-Earnings vs Industry: HGH is expensive based on its Price-To-Earnings Ratio (13.1x) compared to the Global Banks industry average (9.1x)
What is HGH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Current PE Ratio | 13.1x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HGH's Price-To-Earnings Fair Ratio for valuation analysis.
What is the Fair Price of HGH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HGH (NZ$1.76) is trading below our estimate of fair value (NZ$2.64)
Significantly Below Fair Value: HGH is trading below fair value by more than 20%.
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
How is Heartland Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
8.5%
Forecasted annual earnings growth
Earnings vs Savings Rate: HGH's forecast earnings growth (8.5% per year) is above the savings rate (2.1%).
Earnings vs Market: HGH's earnings (8.5% per year) are forecast to grow faster than the NZ market (5.9% per year).
High Growth Earnings: HGH's earnings are forecast to grow, but not significantly.
Revenue vs Market: HGH's revenue (7.6% per year) is forecast to grow faster than the NZ market (5.6% per year).
High Growth Revenue: HGH's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Future ROE: HGH's Return on Equity is forecast to be low in 3 years time (11.4%).
How has Heartland Group Holdings performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
8.3%
Historical annual earnings growth
Quality Earnings: HGH has a high level of non-cash earnings.
Growing Profit Margin: HGH's current net profit margins (37.5%) are higher than last year (36.8%).
Earnings Trend: HGH's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: HGH's earnings growth over the past year (9.3%) exceeds its 5-year average (8.3% per year).
Earnings vs Industry: HGH earnings growth over the past year (9.3%) exceeded the Banks industry 1.2%.
High ROE: HGH's Return on Equity (11.8%) is considered low.
How is Heartland Group Holdings's financial position? (This company is analysed differently as a bank or financial institution)
Financial Health Score
3/6Financial Health Score 3/6
Asset Level
Allowance for Bad Loans
Low Risk Liabilities
Loan Level
Low Risk Deposits
Level of Bad Loans
Asset Level: HGH's Assets to Equity ratio (8.8x) is low.
Allowance for Bad Loans: HGH has a low allowance for bad loans (38%).
Low Risk Liabilities: 57% of HGH's liabilities are made up of primarily low risk sources of funding.
Loan Level: HGH has an appropriate level of Loans to Assets ratio (87%).
Low Risk Deposits: HGH's Loans to Deposits ratio (171%) is high.
Level of Bad Loans: HGH has a high level of bad loans (2.2%).
What is Heartland Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
6.25%
Current Dividend Yield
Notable Dividend: HGH's dividend (6.25%) is higher than the bottom 25% of dividend payers in the NZ market (2.85%).
High Dividend: HGH's dividend (6.25%) is in the top 25% of dividend payers in the NZ market (6.04%)
Stable Dividend: HGH's dividend payments have been volatile in the past 10 years.
Growing Dividend: HGH's dividend payments have increased over the past 10 years.
Earnings Coverage: With its reasonable payout ratio (68.2%), HGH's dividend payments are covered by earnings.
Future Dividend Coverage: HGH's dividends in 3 years are forecast to be covered by earnings (76.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
0.4yrs
Average management tenure
Mr. Jeffrey Kenneth Greenslade, also known as Jeff, LLB, serves as Chief Executive Officer of Heartland Group Holdings Ltd. He serves as Non-Independent Non-Executive Director of Heartland Bank Limited and...
Compensation vs Market: Insufficient data to establish whether Jeff's total compensation is reasonable compared to companies of similar size in the NZ market.
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
Experienced Management: HGH's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Experienced Board: HGH's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
24 Mar 22 | SellNZ$91,455 | Laura Byrne | Individual | 40,000 | NZ$2.29 | |
15 Dec 21 | SellNZ$94,600 | Laura Byrne | Individual | 40,000 | NZ$2.36 |
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.6%.
OwnershipNameSharesCurrent ValueChange %Portfolio % 69,335,936 NZ$122.0m 18.74% no data 14,933,951 NZ$26.3m 12.56% 100% 12,849,840 NZ$22.6m 0.32% no data 11,416,647 NZ$20.1m 0% no data 10,092,152 NZ$17.8m 0% 0.4% 9,224,351 NZ$16.2m -1.3% no data 7,676,933 NZ$13.5m 0% no data 6,475,976 NZ$11.4m 0% 100% 4,573,924 NZ$8.1m 0% 1.02% 4,566,990 NZ$8.0m 0% no data 3,292,937 NZ$5.8m 0% 9.82% 2,020,855 NZ$3.6m 1.39% no data 1,070,204 NZ$1.9m 0% no data 759,734 NZ$1.3m 1.93% no data 654,526 NZ$1.2m 0% no data 532,829 NZ$937.8k 11.11% no data 252,040 NZ$443.6k 5.95% no data 203,043 NZ$357.4k 0% no data 181,810 NZ$320.0k 0.9% no data 166,573 NZ$293.2k 20.46% no data 158,536 NZ$279.0k 0% no data 157,971 NZ$278.0k 6.89% no data 108,088 NZ$190.2k 103.6% no data 65,420 NZ$115.1k 0% no data 55,170 NZ$97.1k -28.26% no data
Heartland Group Holdings Limited's employee growth, exchange listings and data sources
- Heartland Group Holdings Limited
- Heartland House
- Level 3
- Auckland
- 1023
- New Zealand
HGH | NZSE (New Zealand Stock Exchange) | Yes | New Ordinary Shares | NZ | NZD | Feb 2011 |
HGH | ASX (Australian Securities Exchange) | Yes | New Ordinary Shares | AU | AUD | Feb 2011 |
HGH | CHIA (Chi-X Australia) | Yes | New Ordinary Shares | AU | AUD | Feb 2011 |
73X | BST (Boerse-Stuttgart) | Yes | New Ordinary Shares | DE | EUR | Feb 2011 |
Company Analysis | 2022/09/24 00:00 |
End of Day Share Price | 2022/09/23 00:00 |
Earnings | 2022/06/30 |
Annual Earnings | 2022/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.